IQVIA™ Real-World Insights Bibliography

Uncovering the burden of influenza in children in Portugal, 2008?2018
Author(s): Alberto Caldas Afonso 1 2 3 4, Catarina Gouveia 5 6, Gustavo Januário 7 8, Mafalda Carmo 9, Hugo Lopes 10 11 12, Hélène Bricout 13, Catarina Gomes 14, Filipe Froes 15
Affiliations(s): 1Unidade de Nefrologia Pediátrica, Centro Materno-Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, Portugal. caldasafonso.cmin@chporto.min-saude.pt. 2Centro Hospitalar Universitário Santo António, Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal. caldasafonso.cmin@chporto.min-saude.pt. 3EPIUnit - Instituto de Saúde Pública, Porto, Portugal. caldasafonso.cmin@chporto.min-saude.pt. 4Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional, Porto, Portugal. caldasafonso.cmin@chporto.min-saude.pt. 5Hospital D. Estefânia, Centro Hospitalar Lisboa Central, Lisboa, Portugal. 6Faculdade de Ciências Médicas, Nova Medical School, Lisbon, Portugal. 7Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. 8Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal. 9IQVIA, Barcelona, Spain. 10IQVIA, Lisbon, Portugal. 11NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal. 12Comprehensive Health Research Center - Universidade NOVA de Lisboa, Lisbon, Portugal. 13Sanofi, Lyon, France. 14Sanofi, Lisbon, Portugal. 15Hospital Pulido Valente, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
Publication(s):  Caldas Afonso A, Gouveia C, Januário G, Carmo M, Lopes H, Bricout H, Gomes C, Froes F. Uncovering the burden of Influenza in children in Portugal, 2008-2018. BMC Infect Dis. 2024 Jan 18;24(1):100. doi: 10.1186/s12879-023-08685-z. PMID: 38238649; PMCID: PMC10797867.
Document Type(s): Article,
Countries: Portugal,
Click here for the abstract
C:
Y:
Infectious disease, Respiratory disease,
2024
  L:
A:
English
Burden of illness,
  Add to report
 
 
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
Affiliations(s): "1 Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel 2 Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany 3 German Centre for Diabetes Research (DZD), München-Neuherberg, Germany 4 Department of Health Service Administration, China Medical University, Taichung, Taiwan 5 Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan 6 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 7 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 8 Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan 9 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 10 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 11 Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK 12 Institute of Applied Health Research, University of Birmingham, Birmingham, UK 13 Midlands Health Data Research UK, Birmingham, UK 14 DEMAND Hub, University of Birmingham, Birmingham, UK 15 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden 16 Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland 17 IQVIA Solutions Denmark A/S, Copenhagen, Denmark 18 IQVIA, Espoo, Finland 19 IQVIA, Tartu, Estonia 20 Boehringer Ingelheim International GmbH, Ingelheim, Germany 21 Boehringer Ingelheim International GmbH, US 22 Lilly Deutschland GmbH, Bad Homburg, Germany 23 Steno Diabetes Center Copenhagen, Herlev, Denmark 24 Department of Public Health, University of Copenhagen, Copenhagen, Denmark 25 Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway 26 Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway 27 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA 28 Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain"
Publication(s):  "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636 Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
Document Type(s): Article,
Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care,
  Add to report
 
 
Empagliflozin is Associated with Lower Risk of Cardiovascular Events and All-Cause Mortality in Routine Care in East Asia: Results from the EMPRISE Study
Author(s): Dae Jung Kim (1), Wayne H-H Sheu (2), Wook-Jin Chung (3), Daisuke Yabe (4-7), Kyoung Hwa Ha (1), Masaomi Nangaku (8), Elise Chia-Hui Tan (9), Koichi Node (10), Atsutaka Yasui (11), Weiyu Lei (12), Sunwoo Lee (13), Laura Saarelainen (14), Anouk Deruaz-Luyet (15), Moe H. Kyaw (16) and Yutaka Seino (4,17), EMPRISE East Asia Study Group
Affiliations(s): "1 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 2 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 3 Department of Cardiovascular Medicine, Gachon University Gil Medical Center, Incheon, South Korea 4 Kansai Electric Power Medical Research Institute, Kobe, Japan 5 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 6 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 7 Division of Metabolism and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan 8 Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan 9 National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, and Institute of Hospital and Healthcare Administration, National Yang-Ming University, Taipei, Taiwan 10 Department of Cardiovascular Medicine, Saga University, Saga, Japan 11 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan 12 Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan 13 Boehringer Ingelheim Korea Ltd, Seoul, Korea 14 IQVIA, Espoo, Finland 15 Boehringer Ingelheim International GmbH, Ingelheim, Germany 16 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA 17 Kansai Electric Power Hospital, Osaka, Japan "
Publication(s):  "JDI journal Virtual Conference: ACC, May 2021"
Document Type(s): Article,
Countries: Japan, Korea, Taiwan,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care, Retrospective cohort analysis,
  Add to report
 
 
Hypercholesterolaemia control in Spain: The same situation with different regional realities
Author(s): Juan Pedro-Botet, Núria Plana, José María Mostaza, Juan José Gómez-Doblas, María Rosa Fernández Olmo, Carlos Escobar Cervantes, José Luis Díaz-Díaz, Raquel Campuzano Ruiz, Pedro Valdivielso, Juan Cosín-Sales
Affiliations(s): Unidad de Lípidos y Riesgo Vascular, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España
Publication(s):  Clinica e investigacion en arteriosclerosis: publicacion oficial de la Sociedad Espanola de Arteriosclerosis, S0214-9168(23)00027-X. 27 Apr. 2023, doi:10.1016/j.arteri.2023.04.001
Document Type(s): Abstract,
Countries: Spain,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2023
  L:
A:
Spanish
Clinical setting: Primary care, Public Health, Quality of life, Survey research,
  Add to report
 
 
Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions
Author(s): Oriol Sola- Morales (1), Lesley H. Curtis (2), Julien Heidt (3),*, Laura Walsh (4), Deborah Casso (5),?, Susan Oliveria (6),?, Patrick Saunders- Hastings (7), Yufei Song (8),?, Tiffany Mercado (3), Robbert Zusterzeel (3),?, Vera Mastey (9), James Harnett (9) and Ruben G. W. Quek (9)
Affiliations(s): (1) Fundació Health Innovation Technology Transfer and International, University of Catalonia, Barcelona, Spain; (2) Duke Clinical Research Institute, Durham, North Carolina, USA; (3) IQVIA, Regulatory Science and Strategy, Falls Church, Virginia, USA; (4) IQVIA, Epidemiology and Drug Safety Practice, Boston, Massachusetts, USA; (5) IQVIA, Epidemiology and Drug Safety Practice, Seattle, Washington, USA; (6) IQVIA, Epidemiology and Drug Safety Practice, New York, New York, USA; (7) Epi Excellence LLC, Garnet Valley, Pennsylvania, USA; (8) IQVIA, Epidemiology and Drug Safety Practice, Beijing, China; (9) Regeneron Pharmaceuticals Inc., Health Economics & Outcomes Research, Tarrytown, New York, USA
Publication(s):  Clinical pharmacology and therapeutics vol. 114,2 (2023): 325-355. doi:10.1002/cpt.2914
Document Type(s): Article,
Countries: Europe, USA,
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Methodology, Regulatory,
2023
  L:
A:
English
Review,
  Add to report
 
 
Regulatory and HTA Considerations for Development of Real- World Data Derived External Controls
Author(s): Lesley H. Curtis (1), Oriol Sola-Morales (2), Julien Heidt (3),*, Patrick Saunders- Hastings (4), Laura Walsh (5), Deborah Casso (6),?, Susan Oliveria (7),?, Tiffany Mercado (3), Robbert Zusterzeel (3),?, Rachel E. Sobel (8), Jessica J. Jalbert (9), Vera Mastey (9), James Harnett (9) and Ruben G. W. Quek (9)
Affiliations(s): 1Duke Department of Population Health Sciences and Duke Clinical Research Institute, Durham, North Carolina, USA; 2Fundació HiTT and Universitat Internacional de Catalunya (UIC), Barcelona, Spain; 3IQVIA, Regulatory Science and Strategy, Falls Church, Virginia, USA; 4Epi Excellence LLC, Garnet Valley, Pennsylvania, USA; 5IQVIA, Epidemiology and Drug Safety Practice, Boston, Massachusetts, USA; 6IQVIA, Epidemiology and Drug Safety Practice, Seattle, Washington, USA; 7IQVIA, Epidemiology and Drug Safety Practice, New York, New York, USA; 8Regeneron Pharmaceuticals Inc., Pharmacoepidemiology, Tarrytown, New York, USA; 9Regeneron Pharmaceuticals Inc., Health Economics & Outcomes Research, Tarrytown, New York, USA.
Publication(s):  Clin Pharmacol Ther, 114: 303-315. https://doi.org/10.1002/cpt.2913
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Methodology, Regulatory,
2023
  L:
A:
English
Review,
  Add to report
 
 
Cost-effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration in Japan
Author(s): Yasuo Yanagi 1, Kanji Takahashi 2, Tomohiro Iida 3, Fumi Gomi 4, Junko Morii 5, Eriko Kunikane 6, Taiji Sakamoto 7 (rwesheorj 5)
Affiliations(s): 1) Department of Ophthalmology and Microtechnology, Yokohama City University, Kanagawa, Japan 2) Department of Ophthalmology, Kansai Medical University, Osaka, Japan 3) Department of Ophthalmology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan 4) Department of Ophthalmology, Hyogo Medical University, Hyogo, Japan 5) IQVIA Solutions Japan, K.K., Tokyo, Japan 6) Senju Pharmaceutical Co., Ltd., Osaka, Japan 7) Department of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
Publication(s):  Ophthalmology and Therapy
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C:
Y:
Vascular disease,
2023
  L:
A:
English
Cost analysis, Cost effectiveness,
  Add to report
 
 
Assessing definitions and incentives adopted for innovation for pharmaceutical products in five high-income countries: a systematic literature review
Author(s): Naohiko Wakutsu 1, Emi Hirose 2, Naohiro Yonemoto 3, Sven Demiya 4 (rwesheorj 4)
Affiliations(s): 1) Graduate School of Economics, Nagoya City University, Nagoya, Japan 2) Health & Value, Pfizer Japan Inc., Tokyo, Japan. emi.hirose@pfizer.com 3) Health & Value, Pfizer Japan Inc., Tokyo, Japan 4) IQVIA Solutions Japan K.K., Tokyo, Japan
Publication(s):  Pharmaceutical Medicine
Document Type(s): Article,
Countries: France, Germany, Japan, UK, USA,
Click here for the abstract
C:
Y:
Miscellaneous,
2023
  L:
A:
English
Literature Review,
  Add to report
 
 
Patient burden associated with treatment-resistant or unexplained chronic cough - a qualitative study based on focus group interviews
Author(s): Naoya Ueda 1, Anzu Yakushiji 2, Shigeru Tokita 1, Takekazu Kubo 1 (rwesheorj 2)
Affiliations(s): 1) MSD Co., Ltd., Medical Affairs 2) IQVIA Solutions Japan K.K., Tokyo, Japan
Publication(s):  Progress in Medicine
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C:
Y:
Respiratory disease,
2023
  L:
A:
Japanese
Burden of illness, Patient questionnaire,
  Add to report
 
 
Identification and management of connective tissue disease-associated interstitial lung disease: evidence-based Japanese consensus statements
Author(s): Masataka Kuwana 1, Masashi Bando 2, Yutaka Kawahito 3, Shinji Sato 4, Takafumi Suda 5, Yasuhiro Kondoh 6; CTD-ILD Delphi Collaborators (rwesheorj A)
Affiliations(s): 1) Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. 2) Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Tochigi, Japan. 3) Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. 4) Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan. 5) Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. 6) Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
Publication(s):  Expert Review of Respiratory Medicine
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C:
Y:
Respiratory disease,
2023
  L:
A:
English
Literature Review, Survey research,
  Add to report
 
 
 1 of 434 Next Page Last Page